A phase III multicenter, open label, single treatment clinical study to evaluate the safety and efficacy of FDC of Telmisartan 80/40/20mg + Amlodipine 10/5/2.5mg + Hydrochlorthiazide 25/12.5/12.5mg tablet in mild, moderate and severe hypertensive patients.
Phase of Trial: Phase III
Latest Information Update: 30 Aug 2016
At a glance
- Drugs Amlodipine/telmisartan/hydrochlorothiazide (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Vapi Care Pharma
- 11 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by Clinical Trials Registry - India record.
- 27 Mar 2010 New trial record